ABOUT

Founding

November 2019

Headquarters

San Mateo, CA

Stage

Series B

Employees

157

Notable Investors

Andreessen Horowitz, Rock Springs Capital, Incyte, NVIDIA, Menlo Ventures, T. Rowe Price, Fidelity, Radical Ventures

CORE METRICS

Amount

Date

Upfront consideration from Incyte

May 2026

Eligible funding from hitting milestones

May 2026

Pearl system zero-shot success rate on the OpenBind benchmark

June 2026

ADDRESSABLE MARKET

Estimated Size

Year of Estimate

Small molecule drug sales

2023

Global cancer medicine spending

2024

Small molecule drug discovery

2023

© 2026 Contrary Research · All rights reserved

Privacy Policy

By navigating this website you agree to our privacy policy.